Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea penetration, ocular distribution and efficacy studies

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 2, 2012, Pages 257-264

  Di Tommaso, Claudia ^a   Bourges, Jean Louis ^b,c   Valamanesh, Fatemeh ^b,d   Trubitsyn, Gregory ^a   Torriglia, Alicia ^b,c,e,f   Jeanny, Jean Claude ^b   Behar Cohen, Francine ^b,c   Gurny, Robert ^a   Möller, Michael ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^e ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Corneal transplantation; Cyclosporin A; Ocular drug delivery; Polymeric micelles; Topical application

Indexed keywords

CYCLOSPORIN A; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE)GLYCOL; NANOCARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORNEA EDEMA; CORNEA GRAFT REJECTION; CORNEA OPACITY; CORNEA TRANSPLANTATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; FEMALE; GRAFT REJECTION; IN VIVO STUDY; KERATOPLASTY; MICELLE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RAT; TREATMENT OUTCOME;

ABSORPTION; ADMINISTRATION, OPHTHALMIC; ADMINISTRATION, TOPICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; CYCLOSPORINE; DRUG CARRIERS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; KERATOPLASTY, PENETRATING; MICELLES; OPHTHALMIC SOLUTIONS; RATS; RATS, INBRED BN; RATS, INBRED LEW; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 84861592634     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.02.014     Document Type: Article

References (44)

1. Y. Qazi, G. Wong, B. Monson, J. Stringham, and B.K. Ambati Corneal transparency: genesis, maintenance and dysfunction Brain Res. Bull. 81 2010 198 210
2. K.A. Williams, and D.J. Coster The immunobiology of corneal transplantation Transplantation 84 2007 806 813
3. W.H. Constad, and K. Taraschanskiy Immunology of corneal transplantation Clin. Rev. Allergy Immunol. 20 2001 215 241
4. World Health Organization, Human Organ and Tissue, Transplantation, 2003, EB112/5.
5. S. Banerjee, and A.D. Dick Recent developments in the pharmacological treatment and prevention of corneal graft rejection Expert Opin. Investig. Drugs 12 2003 29 37
6. L.X. Xie, W.Y. Shi, Z.Y. Wang, J.Z. Bei, and S.G. Wang Effect of a cyclosporine A delivery system in corneal transplantation Chin. Med. J. 115 2002 110 113
7. M.J. Mihatsch, M. Kyo, K. Morozumi, Y. Yamaguchi, V. Nickeleit, and B. Ryffel The side-effects of cyclosporine-A and tacrolimus Clin. Nephrol. 49 1998 356 363
8. J.I. Italia, V. Bhardwaj, and M.N.V. Kumar Ravi Disease, destination, dose and delivery aspects of ciclosporin: the state of the art Drug Discov. Today 11 2006 846 854
9. K. Mondon, M. Zeisser-Labouebe, R. Gurny, and M. Möller Novel cyclosporin A formulations using MPEG-hexylsubstituted polylactide micelles: a suitability study Eur. J. Pharm. Biopharm. 77 2011 56 65
10. J.-L. Bourges, F. Lallemand, E. Agla, K. Besseghir, J.M. Dumont, D. BenEzra, R. Gurny, and F. Behar-Cohen Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats Mol. Vis. 12 2006 1461 1466
11. I. Yenice, M.C. Mocan, E. Palaska, A. Bochot, E. Bilensoy, I. Vural, M. Irkeç, and A. Hincal Hyaluronic acid coated poly-3-caprolactone nanospheres deliver high concentrations of cyclosporin A into the cornea Exp. Eye Res. 87 2008 162 167
12. L. Gan, Y. Gan, C. Zhu, X. Zhankg, and Y. Zhu Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results Int. J. Pharm. 365 2009 143 149
13. E.H. Gocke, G. Sandri, M.C. Bonferoni, S. Rossi, F. Ferrari, T. Guneri, and C. Caramella Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity Int. J. Pharm. 364 2008 76 86
14. J.R. Juberias, M. Calonge, S. Gomez, M.I. Lopez, P. Calvo, J.M. Herreras, and M.J. Alonso Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat Curr. Eye Res. 17 1998 39 46
15. A.P. Franzco, M.C. Borth, E. Lamoureux, and H.R. Taylor Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial Clin. Exp. Ophthalmol. 36 2008 415 421
16. M. Unal, and I. Yucel Evaluation of topical cyclosporin 0.05% for prevention of rejection in high-risk corneal grafts Br. J. Ophthalmol. 92 2008 1411 1414
17. T. Trimaille, K. Mondon, R. Gurny, and M. Möller Novel polymeric micelles for hydrophobic drug delivery based on biodegradable poly(hexyl-substituted lactides) Int. J. Pharm. 319 2006 147 154
18. K. Mondon, M. Zeisser-Labouebe, R. Gurny, and M. Möller MPEG-hexPLA micelles as novel carriers for hypericin, a fluorescent marker for use in cancer diagnostics Photochem. Photobiol. 87 2011 399 407
19. Y.G. Bachhav, K. Mondon, Y.N. Kalia, R. Gurny, and M. Möller Novel micelle formulations to increase cutaneous bioavailability of azole antifungals J. Control. Release 153 2011 126 132
20. C. Di Tommaso, A. Torriglia, P. Furrer, R. Gurny, and M. Möller Ocular biocompatibility of novel cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers Int. J. Pharm. 416 2011 515 524
21. T. Trimaille, M. Möller, and R. Gurny Synthesis and ring-opening polymerization of new monoalkyl-substituted lactides J. Polym. Sci. Part A: Polym. Chem. 42 2004 4379 4391
22. G. Trubtsyn, et al., ACS Macro Letters, submitted for publication.
23. C. Di Tommaso, C. Como, R. Gurny, and M. Möller Investigations on the lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations Eur. J. Pharm. Sci. 40 2010 38 47
24. M. Rodriguez-Aller, B. Kaufmann, D. Guillarme, C. Stella, I. El Zaoui, F. Valamanesh, C. Di Tommaso, F. Behar-Cohen, J.-L. Veuthey, and R. Gurny In vivo characterisation of a novel water-soluble cyclosporine A prodrug for the treatment of dry eye disease Eur. J. Pharm. Biopharm. 2011 (org/10.1016/j.ejpb. 2011.11.07)
25. K. Järvinen, T. Järvinen, and A. Urtti Ocular absorption following topical delivery Adv. Drug Deliv. Rev. 16 1995 3 19
26. E. Bertelmann, J. Jaroszewski, and U. Pleyer Corneal allograft rejection: current understanding Ophthalmologica 216 2002 2 12
27. J. Theng, L. Zhou, D. Tan, and K.-W. Lam Distribution of cyclosporin A in the cornea after topical or oral administration J. Ocul. Pharmacol. 18 2002 83 88
28. C. Di Tommaso, F. Behar-Cohen, R. Gurny, and M. Möller Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye Ann. Pharm. Fr. 69 2011 116 123
29. B. del Castillo, M. José, C. del Aguila, S. Duran, J. Hernandez, and J.G. Sánchez Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability Cornea 13 1994 136 140
30. E.J. Holland, C.-C. Chan, R.P. Wetzig, A.G. Palestine, and R.B. Nussenblatt Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model Cornea 10 1991 374 380
31. L. Krause, S.E. Coupland, and F. Hoffmann The behavior of ED1- and ED1-positive cells in the rat iris and choroid following penetrating keratoplasty and cyclosporin A therapy Graefes Arch. Clin. Exp. Ophthalmol. 234 1996 S149 S150
32. B. Gridelli, L. Scanlon, R. Pellicci, R. LaPointe, A. DeWolf, H. Seltman, W. Diven, B. Shaw, T. Starzl, and A. Sanghvi Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog Transplantation 41 1986 388 391
33. P. Hsauyry, E. von Willebrand, E. Parthenais, A. Nemlander, A. Soots, I. Lautenschalager, P. Alfoldy, and R. Renkonen The inflammatory mechanisms of allograft rejection Immunol. Rev. 77 1984 85 142
34. I. Ahmed, and T.F. Patton Importance of the noncorneal absorption route in topical ophthalmic drug delivery Invest. Ophth. Vis. Sci. 26 1985 584 587
35. R.L. Kaswan Intraocular penetration of topically applied cyclosporine Transplant. Proc. 20 1988 650 655
36. R.B. Nussenblatt, W.J. Dinning, L.S. Fujikawa, C.-C. Chan, and A.G. Palestine Local cyclosporine therapy for experimental autoimmune uveitis in rats Arch. Ophthalmol. 103 1985 1559 1562
37. M. Kuwano, H. Ibuki, N. Morikawa, A. Ota, and Y. Kawashima Cyclosporine A formulation affect its ocular distribution in rabbits Pharm. Res. 19 2002 108 111
38. W. Johnson Jr., Cosmetic Ingredient Review Expert Panel, Authors not reported, Final Report on the Safety Assessment of Ricinus Communis (Castor) Seed Oil, Hydrogenated Castor Oil, Glyceryl Ricinoleate, Glyceryl Ricinoleate SE, Ricinoleic Acid, Potassium Ricinoleate, Sodium Ricinoleate, Zinc Ricinoleate, Cetyl Ricinoleate, Ethyl Ricinoleate, Glycol Ricinoleate, Isopropyl Ricinoleate, Methyl Ricinoleate, and Octyldodecyl Ricinoleate, Int. J. Toxicol. 26 (2007) 31-77.
39. M.O. Price, and F.W. Price Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes Ophthalmology 113 2006 1785 1790
40. A. Reis, T. Reinhard, and R. Sundmacher Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model Br. J. Ophthalmol. 82 1998 700 703
41. F. Birnbaum, D. Bohringer, Y. Sokolosvka, R. Sundmacher, and T. Reinhard Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study Transplantation 79 2005 964 968
42. W.F.I. Shepherd, D.J. Coster, T. Chin Fook, N.S.C. Rice, and B.R. Jones Effect of cyclosporin A on the survival of corneal grafts in rabbits Br. J. Ophthalm. 64 1980 148 153
43. E. Bertelmann, and U. Pleyer Immunomodulatory therapy in ophthalmology - is there a place for topical applications? Ophthalmologica 218 2004 359 367
44. A.I. Vallelado, M.I. Lopez, M. Calonge, A. Sanchez, and M.J. Alonso Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats Curr. Eye Res. 24 2002 39 45